美國的生技仿製藥及後續生物製品市場(2011∼2020年):問題，展望及預測

美國的生技仿製藥及後續生物製品市場(2011∼2020年):問題，展望及預測 是由出版商IMARC Group在2011年07月所出版的。 這份英文市場調查報告書價格從美金1200起跳。

簡介

生技仿製藥在2010年的銷售額提高到5,700萬美元，但離許多分析師所預期的10億美元銷售額還有一段距離。但一般預計18種生物醫藥品分子在2011∼2020年將跟生技仿製藥展開競爭，而美國的生技仿製藥市場預計將在2020年為止達到114億美元。

本報告提供美國的生技仿製藥市場統計分析，市場現況和實際成果，今後的銷售額預測，各分子類型趨勢等彙整資料，為您概述為以下內容。。

第1章 市場定義和調查方法

第2章 執行摘要

第3章 美國的生技仿製藥相關法規

• Biologics Price Competition and Innovation Act:概要
• 不受支持的生物仿製藥麵臨的挑戰
• 影響生物製藥製造商商務策略的主要課題
  • 兼容性和替代性
  • 數據獨佔
  • 專利訴訟

第4章 美國的生技仿製藥市場環境

第5章 美國的生技仿製藥市場:現狀

• 生長激素生物仿製藥的實際成果到目前為止並不樂觀
• Omnitrope的處方模式
• 小兒科是生長激素的主要顧客群
• Omnitrope推出了一個不方便的給藥系統
• 取得市售後安全數據良好結果的累積預計將會增加

第6章 美國的生技仿製藥市場:價格，銷售量，銷售額減少的結果

• Omnitrope不能作為衡量其他生技仿製藥業績的標準
• 歐洲的ESA及GCSF攝取數量為美國帶來正面的展望
• 各生物製藥類型的生物仿製藥銷售量
• 各生物製藥類型的生技仿製藥的售價
• 各生物製藥類型的生技仿製藥的銷售額減少

第7章 美國的生技仿製藥市場:目前趨勢與各藥物預測

• 生長激素
• 促紅細胞生成素
• 顆粒細胞增生因子
• 胰島素
• 干擾素
• 癌細胞單克隆抗體
• TNFα

第8章 美國的生技仿製藥市場:各適應症目前趨勢與預測

• 免疫疾病學和炎症
• 糖尿病
• 癌症
• 血液疾病
• 發育不良

第9章 競爭環境

• 品牌產品製造商
• 生技仿製藥產品製造商
• 企業簡介
  • Teva
  • Sandoz
  • Hospira
  • Stada
  • Dr Reddy's

圖表

目錄

Abstract

With sales worth US$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential that most analysts believe they will generate. This market, however, unlike small molecule generics, is expected to be a marathon and not a sprint. IMARC Group, one of the world' s leading research and advisory firms, in its new report “US Biosimilar & Follow-On Biologics Market Report (2011-2020): Problems, Prospects & Projections” finds that with eighteen biopharmaceutical molecules expected to face biosimilar competition during 2011 and 2020, the market for biosimilars in the US is expected to reach values worth US$ 11.4 Billion by 2020.

Findings from the report suggest that the historical performance of Omnitrope cannot be taken as a benchmark to gauge the potential of pipeline biosimilars as market acceptance for each biosimilar class is expected to significantly vary from one another. The report expects competition between branded biological drugs and their biosimilar counterparts to represent more that of a brand-brand competition than a brand-generic competition. The high costs involved in the development and launch of biosimilars is expected to limit the number of players in this market and expected to create a significantly lower price and volume erosion compared to that of small molecule generics.

IMARC' s new report entitled “US Biosimilar & Follow-On Biologics Market Report (2011-2020): Problems, Prospects & Projections” provides an analytical and statistical insight into the US biosimilar market. The study that has been undertaken using both desk-based as well as qualitative primary research has analyzed six aspects of the US biosimilar market

Key Aspects Analyzed:

Understanding the Current Legislations on Biosimilars:

• An insight into the Biologics Price Competition and Innovation Act
• An insight on the key biosimilar issues that still remain unaddressed
• Interchangeability and Substitutability
• Data Exclusivity
• Provisions for patent litigation

Evaluating the Current Market Landscape for Biosimilars:

• Identification of current marketed biosimilars and their historical performance
• Identifying the reasons for the slow uptake of current marketed biosimilars
• Analyzing historical data to formulate conclusions on the future growth and trends of biosimilars

Evaluating the Extent of Biosimilar Price, Sales and Volume Erosion:

• Analyzing historical time series data on price, volume and sales erosion in the US & Europe
• Analyzing previous models and assumptions on biosimilar price and volume erosion
• Evaluating and comparing biosimilar price and volume erosion with that of small molecule generics
• Evaluating and comparing biosimilar price, volume and sales erosion across various biological classes

Evaluating the Sales and Volume Erosion of Biosimilars across Various Molecules:

Molecules Covered: Somatropin, Epoitin Alfa, Darbepoetin Alfa, Filgrastim, Pegfilgrastim, Insulin Lispro, Insulin Glargin, Insulin Detemir, Interferon Beta-1A, Interferon Beta-1B, Bevacizumab, Trastuzumab, Rituximab, Cetuximab, Ethanercept, Infliximab and Adalimumab

Focus of the Analysis for Each Molecule:

• Historical Background and Overview
• Historical Brand Sales
• Brand and Biosimilar Sales Forecast

Evaluating the Sales of Biosimilars across Various Indications:

Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders and Growth Deficiency

Focus of the Analysis for Each Indication:

• Historical Brand Sales
• Brand & Biosimilar Sales Forecast
• Biosimilar Sales Forecast by Molecule

Evaluating the Biosimilar Competitive Landscape:

• Identifying branded biological manufacturers that expect the highest amount of biosimilar erosion
• Identifying biosimilar manufacturers and their current partnerships and pipelines

About IMARC Group

For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

Table of Contents

1. Market Definitions & Research Methodology

2. Executive Summary

3. Biosimilar Legislation in the US

• 3.1. The Biologics Price Competition and Innovation Act: An Insight
• 3.2. Biosimlar Issues that Still Remain Unaddressed
• 3.3. Major Issues Impacting the Business Strategies of Biological Companies
  • 3.3.1. Interchangeability & Substitutability
  • 3.3.2. Data Exclusivity
  • 3.3.3. Patent Litigation

4. The US Biosimilar Market Landscape

5. US Biosimilar Market: Current Experience

• 5.1. The Performance of Growth Hormone Biosimilars Has Been Dismal So Far
• 5.2. Prescribing Patterns for Omnitrope
• 5.3. Pediatrics Represent the Prime Customer Base of Growth Hormones
• 5.4. Omnitrope was Launched with an Inconvenient Delivery Device
• 5.5. Uptake is Likely to Increase with an Accumulation of a Positive Post-Market Safety Data

6. US Biosimlar Market: How Much Price, Volume & Sales Erosion will Result

• 6.1. Omnitrope Cannot be Taken as a Benchmark to Gauge the Performance of Other Biosimilars
• 6.2. The European Uptake of ESA & GCSF Give Us a Very Positive Outlook for the US
• 6.3. Current & Future Biosimilar Volume Erosion Across Various Biological Classes
• 6.4. Current & Future Biosimilar Price Erosion Across Various Biological Classes
• 6.5. Current & Future Biosimilar Sales Erosion Across Various Biological Classes

7. US Biosimilar Market: Current Trends & Forecast by Drug

• 7.1. Growth Hormones
  • 7.1.1. Somatropin (Genotropin/Humatrope/Other HGH)
    • 7.1.1.1. Drug Overview
    • 7.1.1.2. Current Brand & Biosimilar Sales
    • 7.1.1.3. Brand & Biosimilar Forecasts (2011-2020)
• 7.2. Erythropoiesis-Stimulating Agents
  • 7.2.1. Epoetin Alfa (Epogen/Eprex)
    • 7.2.1.1. Drug Overview
    • 7.2.1.2. Historical Brand Sales
    • 7.2.1.3. Brand & Biosimilar Forecasts (2011-2020)
  • 7.2.2. Darbepoetin Alfa (Aranesp)
    • 7.2.2.1. Drug Overview
    • 7.2.2.2. Historical Brand Sales
    • 7.2.2.3. Brand & Biosimilar Forecasts (2011-2020)
• 7.3. Granulocyte Colony Stimulating Factor
  • 7.3.1. Filgrastim (Neupogen)
    • 7.3.1.1. Drug Overview
    • 7.3.1.2. Historical Brand Sales
    • 7.3.1.3. Brand & Biosimilar Forecasts (2011-2020)
  • 7.3.2. Pegfilgrastim (Neulasta)
    • 7.3.2.1. Drug Overview
    • 7.3.2.2. Historical Brand Sales
    • 7.3.2.3. Brand & Biosimilar Forecasts (2011-2020)
• 7.4. Insulin
  • 7.4.1. Insulin Lispro (Humalog)
    • 7.4.1.1. Drug Overview
    • 7.4.1.2. Historical Brand Sales
    • 7.4.1.3. Brand & Biosimilar Forecasts (2011-2020)
  • 7.4.2. Insulin Glargine (Lantus)
    • 7.4.2.1. Drug Overview
    • 7.4.2.2. Historical Brand Sales
    • 7.4.2.3. Brand & Biosimilar Forecasts (2011-2020)
  • 7.4.3. Insulin Detemir (Levemir)
    • 7.4.3.1. Drug Overview
    • 7.4.3.2. Historical Brand Sales
    • 7.4.3.3. Brand & Biosimilar Forecasts (2011-2020)
• 7.5. Interferons
  • 7.5.1. Interferon Beta-1A (Avonex)
    • 7.5.1.1. Drug Overview
    • 7.5.1.2. Historical Brand Sales
    • 7.5.1.3. Brand & Biosimilar Forecasts (2011-2020)
  • 7.5.2. Interferon Beta-1A (Rebif)
    • 7.5.2.1. Drug Overview
    • 7.5.2.2. Historical Biosimilar Sales
    • 7.5.2.3. Brand & Biosimilar Forecasts (2011-2020)
  • 7.5.3. Interferon Beta-1B (Betaferon/Betaseron)
    • 7.5.3.1. Drug Overview
    • 7.5.3.2. Historical Biosimilar Sales
    • 7.5.3.3. Brand & Biosimilar Forecasts (2011-2020)
• 7.6. Oncology Monoclonal Antibodies
  • 7.6.1. Bevacizumab (Avastin)
    • 7.6.1.1. Drug Overview
    • 7.6.1.2. Historical Brand Sales
    • 7.6.1.3. Brand & Biosimilar Forecasts (2011-2020)
  • 7.6.2. Trastuzumab (Herceptin)
    • 7.6.2.1. Drug Overview
    • 7.6.2.2. Historical Biosimilar Sales
    • 7.6.2.3. Brand & Biosimilar Forecasts (2011-2020)
  • 7.6.3. Rituximab (Rituxan)
    • 7.6.3.1. Drug Overview
    • 7.6.3.2. Historical Biosimilar Sales
    • 7.6.3.3. Brand & Biosimilar Forecasts (2011-2020)
  • 7.6.4. Cetuximab (Erbitux)
    • 7.6.4.1. Drug Overview
    • 7.6.4.2. Historical Brand Sales
    • 7.6.4.3. Brand & Biosimilar Forecasts (2011-2020)
• 7.7. TNF Alpha
  • 7.7.1. Etanercept (Enbrel)
    • 7.7.1.1. Drug Overview
    • 7.7.1.2. Historical Brand Sales
    • 7.7.1.3. Brand & Biosimilar Forecasts (2011-2020)
  • 7.7.2. Infliximab (Remicade)
    • 7.7.2.1. Drug Overview
    • 7.7.2.2. Historical Brand Sales
    • 7.7.2.3. Brand & Biosimilar Forecasts (2011-2020)
  • 7.7.3. Adalimumab (Humira)
    • 7.7.3.1. Drug Overview
    • 7.7.3.2. Historical Brand Sales
    • 7.7.3.3. Brand & Biosimilar Forecasts (2011-2020)

8. US Biosimilar Market: Current Trends & Forecast by Indication

• 8.1. Immunology & Inflammation
  • 8.1.1. Current Trends & Forecast
  • 8.1.2. Biosimilar Sales Breakup by Molecule
• 8.2. Diabetes
  • 8.2.1. Current Trends & Forecast
  • 8.2.2. Biosimilar Sales Breakup by Molecule
• 8.3. Oncology
  • 8.3.1. Current Trends & Forecast
  • 8.3.2. Biosimilar Sales Breakup by Molecule
• 8.4. Blood Disorder
  • 8.4.1. Current Trends & Forecast
  • 8.4.2. Biosimilar Sales Breakup by Molecule
• 8.5. Growth Deficiency
  • 8.5.1. Current Trends & Forecast
  • 8.5.2. Biosimilar Sales Breakup by Molecule

9. Competitive Landscape

• 9.1. Branded Manufacturers: Companies Facing the Highest Amount of Biosimilar Erosion
• 9.2. Biosimilar Manufacturers: Companies Gaining the Most From Biosimilar Launches
• 9.3. Key Company Profiles
  • 9.3.1. Teva
  • 9.3.2. Sandoz
  • 9.3.3. Hospira
  • 9.3.4. Stada
  • 9.3.5. Dr Reddy' s

LIST OF FIGURES

• Figure 1 - 1: Model Used to Forecast Brand and Biosimilar Sales
• Figure 4 - 1: US: Biosimilar Market (in Million US$), 2007-2010
• Figure 4 - 2: US: Biosimilar Market Forecast (in Million US$), 2011-2020
• Figure 5 - 1: US: Human Growth Hormone Market: Share of Different Brands & Biosimilars (in %), 2007-2010
• Figure 5 - 2: US: Endocrinologist Prescribing Patterns for Omnitrope (in %), 2008
• Figure 5 - 3: US: Share of Omnitrope in New & Switch Human Growth Hormone Patients, (in %), 2008
• Figure 5 - 4: US: Human Growth Hormone Market: Brand & Biosimilar Patient Share (in %), 2007-2020
• Figure 6 - 1: US, Germany, France, Italy, Spain & UK: Somatropin Biosimilars: Patient Share (in %), 2007-2010
• Figure 6 - 2: Germany, France, Italy, Spain & UK: Epoetin Alfa Biosimilars: Patient Share (in %), 2007-2010
• Figure 6 - 3: US: Percentage of Physicians Expected to Prescribe ESA Biosimilars After They Have Been Launched, (in %), 2010
• Figure 6 - 4: Germany, France, Italy, Spain & UK: Filgrastim Biosimilars: Patient Share (in %), 2008-2010
• Figure 6 - 5: Average Generic Volume Erosion of Molecules Based-on Complex Drug Characteristics, (in %)
• Figure 6 - 6: Average Generic Volume Erosion Across Various Countries From Time Since First Generic Entry, (in %)
• Figure 6 - 7: Average Generic Price Erosion of Molecules Based Upon Complex Drug Characteristics, (in %)
• Figure 6 - 8: Average Generic Price Erosion Across Various Countries From Time Since First Generic Entry
• Figure 6 - 9: Average Brand Price Erosion Across Various Countries From Time Since First Generic Entry
• Figure 7 - 1: US: Biosimilar Market: Share by Molecule (in %), 2011-2020
• Figure 7 - 2: US: Somatropin Market: Brand & Biosimilar Sales Share (in %), 2007-2010
• Figure 7 - 3: US: Somatropin Market: Share of Marketed Brands & Biosimilars (in %), 2007-2010
• Figure 7 - 4: US: Somatropin Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
• Figure 7 - 5: US: Epoetin Alfa: Share of Marketed Brands (in %), 2007-2010
• Figure 7 - 6: US: Epoetin Alfa Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
• Figure 7 - 7 : US: Darbepoetin Alfa Market Forecast: Share of Brand & Biosimilar Sales Forecast (in %), 2011-2020
• Figure 7 - 8 : US: Filgrastim Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
• Figure 7 - 9 : US: Pegfilgrastim Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
• Figure 7 - 10 : US: Insulin Lispro Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
• Figure 7 - 11 : US: Insulin Glargine Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
• Figure 7 - 12 : US: Insulin Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
• Figure 7 - 13 : US: Interferon Beta-1A (Avonex) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
• Figure 7 - 14 : US: Interferon Beta-1A (Rebif) Market: Brand & Biosimilar Sales Share (in %), 2011-2020
• Figure 7 - 15 : US: Interferon Beta-1B Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
• Figure 7 - 16 : US: Bevacizumab Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
• Figure 7 - 17 : US: Trastuzumab Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
• Figure 7 - 18 : US: Rituximab Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
• Figure 7 - 19 : US: Cetuximab Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
• Figure 7 - 20 : US: Ethanercept Market: Brand & Biosimilar Sales Share (in %), 2011-2020
• Figure 7 - 21 : US: Infliximab Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
• Figure 8 - 1: US: Biosimilar Market Forecast: Share by Indication (in %), 2011-2020
• Figure 8 - 2: US: Immunology & Inflammation Market Forecast: Brand & Biosimilar Share (in %), 2011-2020
• Figure 8 - 3: US: Immunology & Inflammation Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020
• Figure 8 - 4: US: Diabetes Market forecast: Brand & Biosimilar Share (in %), 2011-2020
• Figure 8 - 5: US: Diabetes Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020
• Figure 8 - 6: US: Oncology Market Forecast: Brand & Biosimilar Share (in %), 2011-2020
• Figure 8 - 7: US: Oncology Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020
• Figure 8 - 8: US: Blood Disorder Market Forecast: Brand & Biosimilar Sales (in %), 2011-2020
• Figure 8 - 9: US: Blood Disorder Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020
• Figure 8 - 10: US: Growth Deficiency Market: Brand & Biosimilar Share (in %), 2007-2010
• Figure 8 - 11: US: Growth Deficiency Market Forecast: Brand & Biosimilar Share (in %), 2011-2020
• Figure 9 - 1: US: Innovator Companies Facing the Highest Amount of Biosimilar Sales Erosion (in %), 2010,2013,2016,2020
• Figure 9 - 2: Key Biosimilar Partnerships

LIST OF TABLES

• Table 1 - 1: US Biosimilar/Follow-On Biologics Market: Market Definition & Overview
• Table 3 - 1: US - Overview of Biosimilar Legislations
• Table 3 - 2: Comparison of Patent Protection and Data Exclusivity
• Table 4 - 1: US: Patent Expiries and Biosimilar Launch
• Table 6 - 1: Biosimilar Vulnerability of Various Biopharmaceutical Classes
• Table 6 - 2: Germany, France, Italy, Spain & UK: Epoetin Alfa Biosimilars: Patient Share (in %), 2007-2010
• Table 6 - 3: US: Various Studies & Assumptions for Biosimilar Volume Erosion
• Table 6 - 4: US, Germany and UK: Biosimilar Volume Penetration After 5 years from Launch (in %)
• Table 6 - 5: Various Studies & Assumptions for Biosimilar Price Erosion
• Table 6 - 6: US, Germany and UK: Biosimilar Sales Penetration after 5 years from Launch, (in %)
• Table 7 - 1: US: Biosimilar Sales by Molecule (in Million US$), 2007-2010
• Table 7 - 2: US: Biosimilar Sales by Molecule (in Million US$), 2011-2020
• Table 7 - 3: US: Somatropin: Brand & Biosimilar Market Overview
• Table 7 - 4: US: Somatropin Market: Brand & Biosimilar Sales/Patient Share, 2007-2010
• Table 7 - 5: US: Somatropin Market: Sales of Marketed Brands & Biosimilars (in Million US$), 2007-2010
• Table 7 - 6: US: Somatropin Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
• Table 7 - 7: US: Epoetin alfa: Brand & Biosimilar Market Overview
• Table 7 - 8: US: Epoetin Alfa: Brand Sales (in Millions US$), 2007-2010
• Table 7 - 9: US: Epoetin Alfa: Sales of Marketed Brands (in Million US$), 2007-2010
• Table 7 - 10: US: Epoetin Alfa Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
• Table 7 - 11: US: Darbepoetin Alpha: Brand & Biosimilar Market Overview
• Table 7 - 12: US: Darbepoetin Alpha Market: Brand Sales (in Millions US$), 2007-2010
• Table 7 - 13: US: Darbepoetin Alfa Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
• Table 7 - 14: US: Filgrastim: Brand & Biosimilar Market Overview
• Table 7 - 15: US: Filgrastim Market: Brand Sales (in Millions US$), 2007-2010
• Table 7 - 16: US: Filgrastim Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
• Table 7 - 17: US: Pegfilgrastim: Brand & Biosimilar Market Overview
• Table 7 - 18: US: Pegfilgrastim Market: Brand Sales (in Millions US$), 2007-2010
• Table 7 - 19: US: Pegfilgrastim Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
• Table 7 - 20: US: Insulin Lispro: Brand & Biosimilar Market Overview
• Table 7 - 21: US: Insulin Lispro Market: Brand Sales (in Millions US$), 2007-2010
• Table 7 - 22: US: Insulin Lispro Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
• Table 7 - 23: US: Insulin Glargine: Brand & Biosimilar Market Overview
• Table 7 - 24: US: Insulin Glargine Market: Brand Sales (in Millions US$), 2007-2010
• Table 7 - 25: US: Insulin Glargine Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
• Table 7 - 26: US: Insulin Detemir: Brand & Biosimilar Market Overview
• Table 7 - 27: US: Insulin Detemir Market: Brand Sales (in Millions US$), 2007-2010
• Table 7 - 28: US: Insulin Detemir Market: Brand & Biosimilar Sales/Patient Share, 2011-2020
• Table 7 - 29: US: Interferon Beta-1A (Avonex) Market: Brand & Biosimilar Market Overview
• Table 7 - 30: US: Interferon Beta-1A (Avonex) Market: Brand Sales (in Millions US$), 2007-2010
• Table 7 - 31: US: Interferon Beta-1A (Avonex) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
• Table 7 - 32: US: Interferon Beta-1A (Rebif): Brand & Biosimilar Market Overview
• Table 7 - 33: US: Interferon Beta-1A (Rebif) Market: Brand Sales (in Millions US$), 2007-2010
• Table 7 - 34: US: Interferon Beta-1A (Rebif) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
• Table 7 - 35: US: Interferon Beta-1B: Brand & Biosimilar Market Overview
• Table 7 - 36: US: Interferon Beta-1B Market: Brand Sales (in Millions US$), 2007-2010
• Table 7 - 37: US: Interferon Beta-1B Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
• Table 7 - 38: US: Bevacizumab: Brand & Biosimilar Market Overview
• Table 7 - 39: US: Bevacizumab Market: Brand Sales (in Millions US$), 2007-2010
• Table 7 - 40: US: Bevacizumab Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
• Table 7 - 41: US: Trastuzumab: Brand & Biosimilar Market Overview
• Table 7 - 42: US: Trastuzumab Market: Brand Sales (in Millions US$), 2007-2010
• Table 7 - 43: US: Trastuzumab Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
• Table 7 - 44: US: Rituximab: Brand & Biosimilar Market Overview
• Table 7 - 45: US: Rituximab Market: Brand Sales (in Millions US$), 2007-2010
• Table 7 - 46: US: Rituximab Market: Brand & Biosimilar Sales/Patient Share, 2011-2020
• Table 7 - 47: US: Cetuximab: Brand & Biosimilar Market Overview
• Table 7 - 48: US: Cetuximab Market: Brand Sales (in Millions US$), 2007-2010
• Table 7 - 49: US: Cetuximab Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
• Table 7 - 50: US: Etanercept: Brand & Biosimilar Market Overview
• Table 7 - 51: US: Etanercept Market: Brand Sales (in Millions US$), 2007-2010
• Table 7 - 52: US: Ethanercept Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
• Table 7 - 53: US: Infliximab: Brand & Biosimilar Market Overview
• Table 7 - 54: US: Infliximab Market: Brand Sales (in Millions US$), 2007-2010
• Table 7 - 55: US: Infliximab Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
• Table 7 - 56: US: Adalimumab: Brand & Biosimilar Market Overview
• Table 7 - 57: US: Adalimumab Market: Brand Sales (in Millions US$), 2007-2010
• Table 7 - 58: US: Adalimumab Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
• Table 8 - 1: US: Biosimilars Market: Sales by Indication (in Million US$), 2007-2010
• Table 8 - 2: US: Biosimilar Market Forecast: Sales by Indication (in Million US$), 2011-2020
• Table 8 - 3: US: Immunology & Inflammation Market: Brand Sales (in Million US$), 2007-2010
• Table 8 - 4: US: Immunology & Inflammation Market Forecast: Branded & Biosimilar Sales (in Million US$), 2011-2020
• Table 8 - 5: US: Immunology & Inflammation Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
• Table 8 - 6: US: Diabetes Market: Brand Sales (in Million US$), 2007-2010
• Table 8 - 7: US: Diabetes Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
• Table 8 - 8: US: Diabetes Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
• Table 8 - 9: US: Oncology Market: Brand Sales (in Million US$), 2007-2010
• Table 8 - 10 : US: Oncology Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
• Table 8 - 11 US: Oncology Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
• Table 8 - 12 : US: Blood Disorder Market: Brand Sales (in Million US$), 2007-2010
• Table 8 - 13 : US: Blood Disorder Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
• Table 8 - 14 : US: Blood Disorder Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
• Table 8 - 15 : US: Growth Deficiency Market: Brand & Biosimilar Sales (in Million US$), 2007-2010
• Table 8 - 16 : US: Growth Deficiency Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
• Table 9 - 1: US: Innovator Companies Facing the Highest Amount of Biosimilar Sales Erosion (in Million US$), 2010, 2013, 2016 & 2020
• Table 9 - 3: Selected Public Companies with Biosimilar Activities
• Table 9 - 4: Global: Biosimilar Product Development Status

相關商品

生技仿製藥相關市場調查報告書

生物仿製藥:全球市場現況及未來展望

Biosimilars: Current Situation & Future Prospects, Worldwide

價格 : US $ 3000

出版日期 : 2012年03月

全球生物相似性藥品市場：2010∼2014年

Global Biosimilar Market 2010-2014

價格 : US $ 1500

出版日期 : 2012年02月

全球生技仿製藥市場:樂觀主義復甦？

Global Biosimilars: A return to optimism?

價格 : US $ 2265

出版日期 : 2012年01月

IMARC Group發行的製藥相關市場調查報告書

生物仿製藥市場報告及預測：美國市場（2011∼2020年）

Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)

價格 : US $ 1200

出版日期 : 2011年10月

美國的降膽固醇藥市場報告及預測:專利失效的危機

US Cholesterol Lowering Agents Market Report & Forecast: On the Edge of a Patent Cliff

價格 : US $ 750

出版日期 : 2011年08月

全球醫藥品冷鍊運輸系統市場(2011-16年)

Global Healthcare Cold Chain Logistics Market Report & Forecast (2011-2016)

價格 : US $ 1200

出版日期 : 2011年07月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!